Why Choose Private Prescription for Weight Management?
Private Prescription Route: Wegovy V Mounjaro UK Access
The NHS route for accessing Wegovy or Mounjaro involves GP referral to specialist weight management services, typically resulting in 6+ month waiting lists and strict eligibility criteria. Private prescription eliminates these barriers, offering the same MHRA-licensed treatments through a streamlined process designed for busy lifestyles. Both Wegovy (semaglutide) and Mounjaro (tirzepatide) are available through our GPhC-registered pharmacy (#9012878), ensuring you receive genuine manufacturer products with full regulatory compliance.
The key advantage of private prescription lies in treatment continuity and prescriber expertise. Rather than navigating complex NHS pathways, our clinical team provides ongoing support throughout your weight management journey. Whether you're comparing Wegovy V Mounjaro UK options or seeking guidance on dose escalation, private prescription offers personalised care without the institutional constraints of NHS specialist services.
Wegovy V Mounjaro UK: Pricing and Value Comparison
Wegovy pricing starts at £79.99 for the 0.25mg starter dose, progressing through £94.99 (0.5mg), £99.99 (1mg), £139.99 (1.7mg), to £209.99 for the 2.4mg maintenance dose. Our bundle options provide convenience for multi-month supply, with the Intro Duo (0.25mg & 0.5mg) priced at £169.99 and the Ultimate Stability Trio offering three months of 2.4mg maintenance supply for £649.99. New customers apply code FIRST40 at checkout, while returning customers use DOSE25 to access these transparent prices.
When comparing Wegovy V Mounjaro UK costs, both treatments require similar investment in your health journey, with pricing reflecting the complex manufacturing processes and extensive clinical development. The value proposition extends beyond initial cost—both treatments may support sustainable weight management when combined with reduced-calorie diet and increased physical activity. Private prescription eliminates hidden costs associated with NHS specialist appointments, travel expenses, and extended waiting periods that can delay treatment initiation.
Clinical Evidence: Wegovy V Mounjaro UK Treatment Outcomes
Wegovy demonstrated significant efficacy in the landmark STEP trials, with participants achieving approximately 15% average weight loss at 68 weeks compared to 2.4% with placebo (Wilding et al., NEJM, 2021). The STEP programme encompassed various populations, including individuals with type 2 diabetes who experienced around 9.6% weight reduction, and those receiving intensive behavioural therapy who achieved approximately clinically studied weight loss when taking Wegovy alongside diet and exercise modifications.
Mounjaro's clinical profile stems from the SURMOUNT trial programme, demonstrating its dual GIP and GLP-1 receptor agonist mechanism in weight management applications. When comparing Wegovy V Mounjaro UK evidence, both treatments require combination with lifestyle interventions for optimal outcomes. The SELECT cardiovascular outcomes trial further established Wegovy's 20% reduction in major cardiovascular events, providing additional health benefits beyond weight management for eligible patients.
How Wegovy Works: GLP-1 Receptor Agonist Mechanism
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics a natural hormone responsible for regulating appetite and food intake. This prescription-only medicine works by slowing gastric emptying, promoting feelings of fullness after smaller meals, and potentially reducing food cravings through actions on brain appetite centres. The once-weekly injection using Novo Nordisk's FlexTouch pen system provides consistent medication levels throughout the seven-day dosing interval. Unlike oral weight management treatments, Wegovy's injectable delivery ensures reliable absorption and predictable therapeutic effects. The mechanism extends beyond simple appetite suppression, influencing multiple pathways involved in weight regulation and metabolic health when used alongside a reduced-calorie diet and increased physical activity.
Wegovy V Mounjaro UK: Streamlined Ordering Process
Our private prescription process begins with a comprehensive 3-minute online clinical assessment, covering medical history, current medications, and weight management goals relevant to both Wegovy and Mounjaro prescribing. Qualified prescribers review applications within standard 3 working days, with express 24-hour review available for urgent requirements. Once approved, both treatments are dispatched via next-day cold-chain delivery, maintaining the 2-8°C temperature requirements essential for medication stability. The process requires no GP referral or specialist weight management service involvement, making it ideal for individuals seeking efficient access to clinically proven treatments. Payment processing includes automatic application of discount codes FIRST40 for new customers or DOSE25 for returning patients at checkout.
Storage and Practical Considerations: Wegovy V Mounjaro UK
Wegovy offers superior storage flexibility compared to Mounjaro, remaining stable at room temperature (below 30°C) for up to 6 weeks once removed from refrigeration, versus Mounjaro's 21-day room temperature limit. This advantage proves particularly valuable for frequent travellers or individuals with limited refrigeration access. Both treatments require refrigerated storage at 2-8°C before first use, with clear labelling indicating expiration dates and storage requirements. The FlexTouch pen system used for Wegovy provides precise dose delivery with audible and tactile confirmation of injection completion. Dose escalation follows a mandatory schedule: 0.25mg (weeks 1-4), 0.5mg (weeks 5-8), 1mg (weeks 9-12), 1.7mg (weeks 13-16), and 2.4mg maintenance from week 17 onwards, ensuring optimal tolerability and therapeutic outcomes.
Private Prescription Advantages: Wegovy V Mounjaro UK Accessibility
Private prescription removes the postcode lottery affecting NHS weight management service availability, ensuring consistent access regardless of local commissioning decisions. Many NHS areas restrict access to Wegovy and Mounjaro through complex eligibility criteria and limited specialist capacity, creating artificial barriers to clinically appropriate treatment. Private prescription enables treatment initiation based purely on clinical suitability and patient preference, without administrative delays or funding restrictions.
The continuity of care provided through private prescription proves invaluable when comparing Wegovy V Mounjaro UK options, as prescribers can adjust treatment plans based on individual response and tolerability. This personalised approach contrasts with NHS protocols that may limit treatment switching or dose optimisation due to resource constraints and rigid pathways designed for population-level management rather than individual patient needs.
Making Your Decision: Wegovy V Mounjaro UK Treatment Selection
Both Wegovy and Mounjaro are available from EverydayMeds, with our prescribers able to help determine which treatment aligns with your specific circumstances, lifestyle requirements, and clinical profile. The decision between these prescription-only medicines should consider factors including injection frequency preferences, storage requirements, and previous experience with similar treatments. Our clinical team provides comprehensive guidance during the assessment process, ensuring you receive the most appropriate treatment for your weight management journey. Whether you choose Wegovy or Mounjaro through private prescription, both options offer clinically proven support for sustainable weight management when combined with dietary modifications and increased physical activity. Start your assessment today at https://everydaymeds.co.uk/collections/wegovy, applying discount codes at checkout for transparent, competitive pricing without hidden fees or lengthy NHS waiting periods.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
